vs
Side-by-side financial comparison of SCYNEXIS INC (SCYX) and Velo3D, Inc. (VELO). Click either name above to swap in a different company.
SCYNEXIS INC is the larger business by last-quarter revenue ($18.6M vs $9.4M, roughly 2.0× Velo3D, Inc.). SCYNEXIS INC runs the higher net margin — 65.7% vs -231.9%, a 297.7% gap on every dollar of revenue. On growth, SCYNEXIS INC posted the faster year-over-year revenue change (1808.5% vs -25.2%). Over the past eight quarters, SCYNEXIS INC's revenue compounded faster (268.5% CAGR vs -1.8%).
SCYNEXIS Inc. is a biotechnology company focused on developing innovative antifungal therapies to address unmet medical needs for difficult-to-treat fungal infections. It targets hospital and specialty care markets, with key product candidates serving immunocompromised patients and other high-risk groups.
Velo3D, Inc. develops and sells advanced end-to-end metal additive manufacturing (3D printing) solutions, comprising industrial-grade printers, specialized processing software, and high-performance metal materials. It primarily serves global aerospace, defense, energy, semiconductor and industrial manufacturing markets, enabling customers to produce complex, high-precision metal parts that are difficult to manufacture with traditional methods.
SCYX vs VELO — Head-to-Head
Income Statement — Q4 FY2025 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $18.6M | $9.4M |
| Net Profit | $12.3M | $-21.9M |
| Gross Margin | — | -73.6% |
| Operating Margin | 56.3% | -231.0% |
| Net Margin | 65.7% | -231.9% |
| Revenue YoY | 1808.5% | -25.2% |
| Net Profit YoY | 376.5% | -2.9% |
| EPS (diluted) | $0.25 | $-0.87 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $18.6M | $9.4M | ||
| Q3 25 | $334.0K | $13.6M | ||
| Q2 25 | $1.4M | $13.6M | ||
| Q1 25 | $257.0K | $9.3M | ||
| Q4 24 | $977.0K | $12.6M | ||
| Q3 24 | $660.0K | $8.2M | ||
| Q2 24 | $736.0K | $10.3M | ||
| Q1 24 | $1.4M | $9.8M |
| Q4 25 | $12.3M | $-21.9M | ||
| Q3 25 | $-8.6M | $-11.2M | ||
| Q2 25 | $-6.9M | $-13.3M | ||
| Q1 25 | $-5.4M | $-25.0M | ||
| Q4 24 | — | $-21.3M | ||
| Q3 24 | $-2.8M | $-21.9M | ||
| Q2 24 | $-14.5M | $935.0K | ||
| Q1 24 | $411.0K | $-27.5M |
| Q4 25 | — | -73.6% | ||
| Q3 25 | — | 3.2% | ||
| Q2 25 | — | -11.7% | ||
| Q1 25 | — | 7.5% | ||
| Q4 24 | — | -3.5% | ||
| Q3 24 | — | 49.4% | ||
| Q2 24 | — | -28.0% | ||
| Q1 24 | — | -28.8% |
| Q4 25 | 56.3% | -231.0% | ||
| Q3 25 | -2516.5% | -73.3% | ||
| Q2 25 | -701.0% | -85.4% | ||
| Q1 25 | -3350.2% | -123.6% | ||
| Q4 24 | — | -167.0% | ||
| Q3 24 | -1563.6% | -213.8% | ||
| Q2 24 | -1255.0% | -187.7% | ||
| Q1 24 | -692.5% | -211.1% |
| Q4 25 | 65.7% | -231.9% | ||
| Q3 25 | -2572.2% | -82.0% | ||
| Q2 25 | -504.8% | -97.7% | ||
| Q1 25 | -2097.7% | -268.4% | ||
| Q4 24 | — | -168.5% | ||
| Q3 24 | -425.5% | -265.3% | ||
| Q2 24 | -1964.4% | 9.0% | ||
| Q1 24 | 29.9% | -281.2% |
| Q4 25 | $0.25 | $-0.87 | ||
| Q3 25 | $-0.17 | $-0.65 | ||
| Q2 25 | $-0.14 | $-0.94 | ||
| Q1 25 | $-0.11 | $-1.87 | ||
| Q4 24 | — | $7.06 | ||
| Q3 24 | $-0.06 | $-35.52 | ||
| Q2 24 | $-0.30 | $1.65 | ||
| Q1 24 | $0.01 | $-55.51 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $40.0M | $39.0M |
| Total DebtLower is stronger | — | $31.0M |
| Stockholders' EquityBook value | $49.4M | $38.2M |
| Total Assets | $59.0M | $105.3M |
| Debt / EquityLower = less leverage | — | 0.81× |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $40.0M | $39.0M | ||
| Q3 25 | $37.9M | $11.8M | ||
| Q2 25 | $44.8M | $854.0K | ||
| Q1 25 | $40.6M | $3.9M | ||
| Q4 24 | $59.3M | $1.2M | ||
| Q3 24 | $68.8M | $1.6M | ||
| Q2 24 | $73.0M | $3.2M | ||
| Q1 24 | $80.2M | $10.9M |
| Q4 25 | — | $31.0M | ||
| Q3 25 | — | $23.0M | ||
| Q2 25 | — | $22.5M | ||
| Q1 25 | — | $21.7M | ||
| Q4 24 | — | $5.7M | ||
| Q3 24 | — | $32.3M | ||
| Q2 24 | — | $33.5M | ||
| Q1 24 | — | $44.0M |
| Q4 25 | $49.4M | $38.2M | ||
| Q3 25 | $36.4M | $29.9M | ||
| Q2 25 | $44.5M | $21.4M | ||
| Q1 25 | $50.5M | $32.8M | ||
| Q4 24 | $55.1M | $39.7M | ||
| Q3 24 | $58.5M | $34.4M | ||
| Q2 24 | $60.4M | $52.1M | ||
| Q1 24 | $74.1M | $45.5M |
| Q4 25 | $59.0M | $105.3M | ||
| Q3 25 | $51.1M | $93.7M | ||
| Q2 25 | $60.7M | $78.4M | ||
| Q1 25 | $67.9M | $91.3M | ||
| Q4 24 | $90.6M | $89.2M | ||
| Q3 24 | $99.0M | $110.8M | ||
| Q2 24 | $107.8M | $116.7M | ||
| Q1 24 | $118.3M | $136.1M |
| Q4 25 | — | 0.81× | ||
| Q3 25 | — | 0.77× | ||
| Q2 25 | — | 1.05× | ||
| Q1 25 | — | 0.66× | ||
| Q4 24 | — | 0.14× | ||
| Q3 24 | — | 0.94× | ||
| Q2 24 | — | 0.64× | ||
| Q1 24 | — | 0.97× |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $18.4M | $-7.7M |
| Free Cash FlowOCF − Capex | — | $-8.3M |
| FCF MarginFCF / Revenue | — | -88.3% |
| Capex IntensityCapex / Revenue | — | 6.4% |
| Cash ConversionOCF / Net Profit | 1.50× | — |
| TTM Free Cash FlowTrailing 4 quarters | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $18.4M | $-7.7M | ||
| Q3 25 | $-8.7M | $-6.0M | ||
| Q2 25 | $-7.5M | $-1.2M | ||
| Q1 25 | $-7.5M | $-12.3M | ||
| Q4 24 | $-24.0M | $-2.2M | ||
| Q3 24 | $765.0K | $-2.0M | ||
| Q2 24 | $-10.9M | $-8.0M | ||
| Q1 24 | $-4.0M | $-20.5M |
| Q4 25 | — | $-8.3M | ||
| Q3 25 | — | $-6.3M | ||
| Q2 25 | — | $-3.0M | ||
| Q1 25 | — | — | ||
| Q4 24 | — | $-2.2M | ||
| Q3 24 | — | $-2.0M | ||
| Q2 24 | — | $-8.0M | ||
| Q1 24 | — | $-20.5M |
| Q4 25 | — | -88.3% | ||
| Q3 25 | — | -46.5% | ||
| Q2 25 | — | -22.2% | ||
| Q1 25 | — | — | ||
| Q4 24 | — | -17.7% | ||
| Q3 24 | — | -24.2% | ||
| Q2 24 | — | -77.1% | ||
| Q1 24 | — | -209.8% |
| Q4 25 | — | 6.4% | ||
| Q3 25 | — | 2.3% | ||
| Q2 25 | — | 13.3% | ||
| Q1 25 | — | 0.0% | ||
| Q4 24 | — | 0.2% | ||
| Q3 24 | — | 0.2% | ||
| Q2 24 | — | 0.0% | ||
| Q1 24 | — | 0.1% |
| Q4 25 | 1.50× | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | -8.52× | ||
| Q1 24 | -9.75× | — |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
SCYX
| Glaxosmithkline Intellectual Property | $17.2M | 92% |
| Products | $1.4M | 8% |
VELO
Segment breakdown not available.
